Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Lung Cancer Treatments and Mutations, Lung Cancer Research Studies, Cancer Genomics and Diagnostics, and Cancer Immunotherapy and Biomarkers.
Distinct CD8+ T cell dynamics associate with response to neoadjuvant cancer immunotherapies
Characteristics and anatomic location of PD-1 <sup>+</sup> TCF1 <sup>+</sup> stem-like CD8 T cells in chronic viral infection and cancer
EGFR-phosphorylated GDH1 harmonizes with RSK2 to drive CREB activation and tumor metastasis in EGFR-activated lung cancer
YAP1 Expression in SCLC Defines a Distinct Subtype With T-cell–Inflamed Phenotype
Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study
Epigenetic modulation of FBW7/Mcl-1 pathway for lung cancer therapy
Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience
Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
The Biospecimen Preanalytical Variables Program: A Multiassay Comparison of Effects of Delay to Fixation and Fixation Duration on Nucleic Acid Quality
Mcl-1 Interacts with Akt to Promote Lung Cancer Progression
Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study
Orthopedia homeobox is preferentially expressed in typical carcinoids of the lung
Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent
Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients
Vimentin Is Required for Lung Adenocarcinoma Metastasis via Heterotypic Tumor Cell–Cancer-Associated Fibroblast Interactions during Collective Invasion
Targeting adhesion signaling in KRAS, LKB1 mutant lung adenocarcinoma
Targeting Mcl-1 enhances DNA replication stress sensitivity to cancer therapy
Next‐generation sequencing and clinical outcomes of patients with lung adenocarcinoma treated with stereotactic body radiotherapy
Modulation of Bax and mTOR for Cancer Therapeutics
Lung Adenocarcinoma Staging Using the 2011 IASLC/ATS/ERS Classification: A Pooled Analysis of Adenocarcinoma In Situ and Minimally Invasive Adenocarcinoma
Patient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancer
Clinical Validation and Implementation of a Targeted Next-Generation Sequencing Assay to Detect Somatic Variants in Non-Small Cell Lung, Melanoma, and Gastrointestinal Malignancies
Cardiac allograft rejection as a complication of PD-1 checkpoint blockade for cancer immunotherapy: a case report
Non-neutralizing antibodies induced by seasonal influenza vaccine prevent, not exacerbate A(H1N1)pdm09 disease
Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling
Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy
Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium
Small-molecule Bax agonists for cancer therapy
Poly (<scp>ADP</scp>) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer
Class I HDACs Are Mediators of Smoke Carcinogen–Induced Stabilization of DNMT1 and Serve as Promising Targets for Chemoprevention of Lung Cancer